Ladies, We Need To Talk The Ozempic era
5 snips
Oct 28, 2024 In this engaging conversation, Tegan Taylor, an ABC health and science reporter known for her insightful commentary, delves into the Ozempic phenomenon. She discusses the societal obsession with weight loss, touching on the allure and consequences of rapid slimming solutions. Tegan highlights the disparities in access to these medications and the emotional complexities surrounding body image. The dialogue also addresses the stigma associated with fatness and the moral dilemmas surrounding beauty standards in a world increasingly fixated on thinness.
AI Snips
Chapters
Transcript
Episode notes
Amy's Decades Of Failed Diets Then Rapid Weight Loss
- Amy tried decades of diets, gym classes and even amphetamine-like drugs without lasting success on weight loss.
- After being diagnosed borderline type 2 diabetic, Amy was prescribed Saxenda and within weeks began considerable weight loss where other methods had failed.
How GLP-1 Drugs Actually Work
- GLP-1 agonists like Ozempic, Saxenda, Wegovy and Mounjaro mimic a gut hormone to lower blood sugar and suppress appetite.
- They were developed for type 2 diabetes but their side effect of weight loss drove off-label and approved use for slimming.
Pharmacy Shortages Spark Judgment And Access Fights
- High demand caused shortages and pharmacists sometimes questioned patients' need for GLP-1 drugs, prioritising diabetics.
- Amy experienced judgment at pharmacies despite a GP script saying she was at risk of type 2 diabetes.